Drug page
Semaglutide
Semaglutide is a GLP-1 receptor agonist given as a once-weekly injection or a daily tablet. This page gathers every Diabesity Rounds report that discusses it, newest first.
Reports
- Semaglutide in diabetic kidney disease: primary MRI outcomes not met in 52-week trialRandomised trial · 10 October 2026
- Chemically synthesised semaglutide HD1916 met equivalence with Wegovy for weight loss in Chinese adultsRandomised trial · 10 October 2026
Page updated 10 October 2026.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.